Abstract:Rationale: Pulmonary vascular endotheliitis, perivascular inflammation, and immune activation are observed in COVID-19 patients. While the initial SARS-CoV-2 infection mainly infects lung epithelial cells, whether it also infects endothelial cells (ECs) and to what extent SARS-CoV-2-mediated pulmonary vascular endotheliitis is associated with immune activation remain to be determined. Methods: To address these questions, we studied SARS-CoV-2-infected K18-hACE2 (K18) mice, a severe COVID-19 mouse model, as well as lung samples from SARS-CoV-2-infected nonhuman primates (NHP) and patient deceased from COVID-19. We used immunostaining, RNAscope, and electron microscopy to analyze the organs collected from animals and patient. We conducted bulk and single cell (sc) RNA-seq analyses, and cytokine profiling of lungs or serum of the severe COVID-19 mice. Results: We show that SARS-CoV-2-infected K18 mice develop severe COVID-19, including progressive body weight loss and fatality at 7 days, severe lung interstitial inflammation, edema, hemorrhage, perivascular inflammation, systemic lymphocytopenia, and eosinopenia. Body weight loss in K18 mice correlated with the severity of pneumonia, but not with brain infection. We also observed endothelial activation and dysfunction in pulmonary vessels evidenced by the up-regulation of VCAM1 and ICAM1 and the downregulation of VE-cadherin. We detected SARS-CoV-2 in capillary ECs, activation and adhesion of platelets and immune cells to the vascular wall of the alveolar septa, and increased complement deposition in the lungs, in both COVID-19-murine and NHP models. We also revealed that pathways of coagulation, complement, K-ras signaling, and genes of ICAM1 and VCAM1 related to EC dysfunction and injury were upregulated, and were associated with massive immune activation in the lung and circulation. Conclusion: Together, our results indicate that SARS-CoV-2 causes endotheliitis via both infection and infection-mediated immune activation, which may contribute to the pathogenesis of severe COVID-19 disease.

Endothelial cells and SARS-CoV-2: An intimate relationship

COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection

Endothelial Dysfunction and SARS-CoV-2 Infection: Association and Therapeutic Strategies

Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?

Extracellular vesicles and angiotensin-converting enzyme 2 in COVID-19 disease

SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro

Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19

Modulations of Homeostatic ACE2, CD147, GRP78 Pathways Correlate with Vascular and Endothelial Performance Markers during Pulmonary SARS-CoV-2 Infection

Endothelial cells elicit a pro-inflammatory response to SARS-CoV-2 without productive viral infection

Vascular inflammation and endothelial injury in SARS-CoV-2 infection: the overlooked regulatory cascades implicated by the ACE2 gene cluster

ACE2 As a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect

The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology

Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19

Endothelial cell infection and dysfunction, immune activation in severe COVID-19

Understanding the Impact of SARS-CoV-2 on Lung Endothelial Cells: Brief Mechanisms Unveiled

Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications

ACE2 and Innate Immunity in the Regulation of SARS-CoV-2-Induced Acute Lung Injury: A Review

Role of SARS-COV-2 and ACE2 in the pathophysiology of peripheral vascular diseases

The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19

Viral Endothelial Dysfunction: A Unifying Mechanism for COVID-19

Soluble Angiotensin Converting Enzyme 2 (ACE2) Is Upregulated and Soluble Endothelial Nitric Oxide Synthase (eNOS) Is Downregulated in COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)